74 results about "Bioabsorbable stent" patented technology

A bioabsorbable stent includes one or more radiopaque markers. The stent body may include a generally cylindrical body portion and a marker support for receiving the one or more marker(s). The marker support may be connected to an end of the body portion, or may be an integral portion of the body portion. By selectively controlling dissolution of the biodegradable material of the marker support, the marker support will remain intact for a sufficient time to allow for the marker to endothelialize and therefore prevent the marker from dislodging and embolizing. The controlled dissolution may be accomplished via one or more of the following mechanisms, including increasing the cross-sectional thickness of the marker support, passivating or oxidizing the marker support, utilizing a different, slower absorbing material for the marker support, utilizing a bioabsorbable polymeric coating on the marker support, or protecting the marker support with a sacrificial anode.

A medical device includes a support structure formed of a metal that is absorbable by a mammalian body. A polymer is disposed on the support structure in at least partially overlying relationship. The polymer has a thickness and a rate of absorption by a mammalian body such that said polymer is substantially completely absorbed, exposing the underlying portion of the support structure, before the underlying portion of the support structure is absorbed. In another embodiment, the medical device includes a support structure formed of a first material, the first material being absorbable by a mammalian body. An absorption inhibitor disposed on the support structure in at least partially overlying relationship and formed of a second material different from the first material. The second material being absorbable by the mammalian body. The absorption inhibitor reducing a rate of absorption of the portion of the support structure.

A composite stent structure includes separate and distinct stent elements or members: an outer stent element and an inner stent element removably attached to the outer stent element. The outer element may be, for example, a bioabsorbable stent typically constructed of a relatively non-resilient material such that the outer bioabsorbable stent element may not be self-expanding and subject to migration within the lumen over time. In contrast, the inner element may be, for example, a removable SEMS used to urge and maintain the outer element in position in the body lumen. The temporary inner SEMS may retain the composite structure (including the underlying inner element) in position until such time as the outer element is appropriately incorporated into the surrounding tissue or some other criteria occurs such that the removal of the SEMS is indicated. The SEMS may then be detached from the outer element and removed from the body lumen.

According to an aspect of the present invention, a stent is provided, which contains at least one filament that has a longitudinal axis and comprises a bioabsorbable polymeric material. Polymer molecules within the bioabsorbable polymeric material are provided with a helical orientation which is aligned with respect to the longitudinal axis of the filament. The stent is at least partially bioabsorbed by a patient upon implantation or insertion of the stent into the patient.

A bioabsorbable polymeric stent with time dependent structure and properties and methods of treating a diseased blood vessel with the bioabsorable polymeric stent are disclosed. The structure and properties of the stent change with time and allow the vessel to be restored to a natural unstented state. The bioabsorbable stent loses mechanical integrity in a controlled manner due to modification of selected structural elements.

Biodegradable/bioabsorbable stent anchors are provided to prevent stent migration and permit repositioning and/or removal of the stent after the anchors or portion thereof has sufficiently degraded or been absorbed.

Bioabsorbable polymer scaffolds with coatings are disclosed that include immobilized antithrombotic agents on the scaffolds or in or on the coatings. The agents act synergistically with antiproliferative agents released from coatings by providing hemocompatibility during and without interfering with antiproliferative agent release. Methods of modifying scaffolds and coatings with the antithrombotic agents are disclosed.

A method and instruments used to performing an end-to-end anastomosis between two portions of intestinal tissue is disclosed. The method involves drawing a first portion of intestinal tissue over a portion of a bioabsorbable stent. The end of the first portion of intestinal tissue is everted on the stent to create a collar of exposed inner intestinal tissue. A second portion of intestinal tissue is drawn over the stent and over the exposed intestinal tissue. A bandage containing one adhesive compound selected from the group of an adhesive and an adhesive initiator is wrapped about the juncture. The other adhesive compound is applied to saturate the bandage and the combination of an adhesive and an adhesive initiator sets the adhesive to adhere the first portion and the second portion of adhesive to the bandage.

Tubular casting processes, such as dip-coating, may be used to form substrates from polymeric solutions which may be used to fabricate implantable devices such as stents. The polymeric substrates may have multiple layers which retain the inherent properties of their starting materials and which are sufficiently ductile to prevent brittle fracture. Parameters such as the number of times the mandrel is immersed, the duration of time of each immersion within the solution, as well as the delay time between each immersion or the drying or curing time between dips and withdrawal rates of the mandrel from the solution may each be controlled to result in the desired mechanical characteristics. Additional post-processing may also be utilized to further increase strength of the substrate or to alter its shape.

The invention relates to the field of medical devices, and more specifically discloses a biodegradable stent based on a modified polylactic acid or a polylactic acid copolymer, and a preparation method thereof. According to the present invention, a linear polylactic acid or polylactic acid copolymer with a high molecular weight is blended with a biodegradable cross-linking agent, injection extrusion, injection molding or other processing methods are adopted to prepare a pipe material, the pipe material is subjected to a cross-linking polymerization reaction to form a semi-interpenetrating polymer network, and finally laser cutting is adopted to obtain the stent. The stent has characteristics of sufficient mechanical strength, sufficient structural stability, and improved processability.

A bioabsorbable tracheal stent is provided. The bioabsorbable stent comprises a biodegradable polymer, wherein the “ biodegradable polymer comprises about 0 to 30 wt % glycerol, polyethylene glycol, triethyl citrate, or mixture thereof. A drug is dispersed within or dissolved in the biodegradable polymer. In a second and third aspect, the invention relates to methods of manufacturing a bioabsorbable tracheal stent. The first method includes forming a solution comprising a biodegradable polymer and a drug, the biodegradable polymer comprising about 0 to 30 wt % glycerol, polyethylene glycol, triethyl citrate, or mixture thereof. The method further comprises casting the solution to form the bioabsorbable tracheal stent. The second method includes forming a polymeric stent, and dip casting the polymeric stent in a solution comprising a biodegradable polymer and a drug to form a coating on the polymeric stent, wherein the biodegradable polymer comprises about 0 to 30 wt % glycerol, polyethylene glycol, triethyl citrate, or mixture thereof.

Provided herein is a medical device that includes RGD attached to the device via a spacer compound.

Embodiments of the present invention include methods for the treatment, prevention, or amelioration of vascular disease and/or disorder in diabetic patients. The methods include implantation of a stent including a drug, and the use of a drug coated balloon. The DES may be a DES having a metal body and a coating including the drug, or a bioabsorbable stent with drug in the body of the stent, in a coating on the stent, or both in the body of the stent and in a coating on the stent.

The invention provides a biodegradable bracket with multiple drugs, belongs to the field of medical equipment and relates to a biodegradable bracket with a single coating. Besides support function, the bracket further comprises the single coating which contains anti-proliferative drugs, anti-inflammation and anti-immune drugs, drugs for promoting endothelial cells to grow and a developing agent. The bracket main body is made of biodegradable polymers of which mechanical strength is high. After implanted on a pathological position, the bracket has strong support force, so that action of supporting the pathological vessels in short time can be achieved. Because of the developing agent, doctors can accurately obverse the position and the expansion consistency of the bracket during operation, and displacement or other adverse events can be prevented; the anti-proliferative drugs can prevent the vessels from becoming narrow in short time after the bracket is implanted; and the drugs for promoting the endothelial cells to grow can promote the endothelial cells to grow on the surface of the bracket and can cover the bracket in the endothelium of the vessels, so that embolism phenomenon caused by degradation fragments of the bracket dropping in blood can be prevented.

An expandable, bioabsorbable stent having a coiled-coil configuration is described. The stent further comprises regions of variable pitch that allow for variation in either rigidity, or variability diameter within sub-regions along the length of the deployed stent. By varying the diameter allows the stent to extend into regions such as branched vessels, or into the neck of aneurysms. In some embodiments, the stent comprises longitudinal support fibers that run substantially the length of the deployed stent to provide additional strength. In addition, the stent may also comprise regional support fibers that run less than the length of the stent, and which provide increased regional strength while permitting flexibility of the stent. The stent further comprises micro-tubes that are configured to be visible using medical imaging techniques. The stent can be manufactured from materials that are bioabsorbable and/or include the ability to release pharmacologically active substances over time.

A stent assembly (10) is formed with a plurality of stent rings (12) which have sections (16, 18, 24) which are of a non-biodegradable material and struts and tie bars (20, 14) which are at least partially biodegradable. The stent ring (12) thus partially biodegrades in a patient over time. The structure is such that the apices (16, 18, 24) of the stent ring (12) are of a non-biodegradable material and thus able to behave as a conventional non-biodegradable stent, that is with the same flexibility and expansion force consistent with such stent rings. Parts (34, 44) of the stent ring (12) will degrade in time, thereby reducing the restoring force produced by the stent ring (12) and reducing the amount of foreign material retained within a patient's body. In one embodiment, the stent ring (12) will separate into individual components after a period.